A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

NCT06311721 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

315

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

Interventions

DRUG: ABP 234
DRUG: Pembrolizumab (US)
DRUG: Pembrolizumab (EU)

Sponsor

Amgen